Intracranial Arteriosclerosis clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 30 years and up
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
La Jolla, California and other locations
Our lead scientists for Intracranial Arteriosclerosis research studies include Dawn Meyer.